AU
CA
NZ
UK
US
IND
Key HighlightsAustralasia's largest healthcare and pharmaceutical distributor commanding essential position in supply chainH1 revenue growth of 13% reaching $6.8B demonstrates strong market momentum and acquisition integrationHealthcare segment EBITDA of $254M reflecting stable underlying business supporting dividend distributionsAnimal Care segment EBITDA growth of 15.1% to …
Key HighlightsStock trading at $0.71, down 8.97% from recent levels and 53% below $1.50 IPO price (December 2025)Only FDA-authorized implantable continuous EEG monitoring system for epilepsy managementCochlear Limited holds 36% strategic stake, backing the technology and commercializationNet loss of $34.5M in FY25, up 54% …
Key HighlightsPathology services provider with high-teens market share in Australia's diagnostic testing sectorH1 revenue of $365.4M declined 1% due to volume pressures from GP-referred decline and Medicare fee cutsUnderlying EBIT improved 2.4% to $28M with EBIT margin expansion of 30 basis points to 7.7%Fixed …
CSL Limited (ASX:CSL) stands as one of the world's leading biopharmaceutical companies, commanding amarket capitalizationnear $69.17 billion as of March 2026. The company's systematic share buyback program demonstrates sustained management confidence, with approximately 3 million shares repurchased since October 2024, including 38,843 shares on …
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is emerging as one of the most compelling biotech investment stories in 2026 as its lead product Ryoncil delivers accelerating commercial revenue and the company expands its clinical leadership team. The dual-listed regenerative medicine company has attracted renewed investor attention …
Acrux Ltd stock drops 11.11% in broad ASX selloff. Specialty pharmaceutical company focuses on topical generic drugs with US market exposure.Key HighlightsAcrux shares decline 11.11% during broad ASX materials and healthcare sector sell-off on geopolitical concernsSpecialty pharma company developing topical pharmaceutical products using proprietary …
Pathology services are essential for healthcare systems, as doctors rely on laboratory tests to diagnose medical conditions and monitor treatment effectiveness.
CSL Behring focuses on plasma therapies used to treat rare and serious diseases, while CSL Seqirus is a leading global influenza vaccine provider. CSL Vifor specializes in treatments for iron deficiency and kidney disease.
Mesoblast operates with dual listings on theASX (MSB)andNASDAQ (MESO), providing international investor access to its regenerative medicine pipeline. The company also maintains a financial position that includesapproximately $130M in cash reserves, supporting ongoing commercialization and clinical development activities.
Telix Pharmaceuticals (ASX:TLX) delivered one of the most striking moves on the Australian Securities Exchange on March 10, 2026. The move reflects growing investor conviction in the Melbourne-based radiopharmaceutical company's transition from a clinical-stage firm to a profitable, globally significant commercial enterprise.
Please wait processing your request...